ROCHESTER — OptimizeRx Corp. (OTCQB:OPRX), an aggregator of pharmaceutical-sponsored services in electronic health records, appointed company director Gus D. Halas as chairman of the board, effective June 30. He will succeed retiring chairman and company founder, David Harrell.
As the company’s CEO until February of last year, Harrell created the first technology and network to automate customized copay savings and other patient support directly within doctors’ existing electronic prescribing workflow.
Continue reading OptimizeRx Names New Board Chair; Founding CEO To Retire
ANN ARBOR — The Ann Arbor-based biopharmaceutical startup RetroSense Therapeutics LLC announced that the United States Patent and Trademark Office has granted U.S. patent Application No. 11,036,629, entitled “Method for Augmenting Vision in Persons Suffering from Photoreceptor Cell Degeneration.”
RetroSense is the exclusive licensee of this intellectual property for augmenting vision from photoreceptor cell degeneration through a license with Massachusetts General Hospital. This patent broadly covers methods for restoring or improving vision using optogenetic approaches. The allowed claims cover the use of a broad range of light-sensitive proteins called opsins and rhodopsins in vision restoration.
Continue reading RetroSense Gets Patent On Method for Restoring Vision
ANN ARBOR — A new drug to treat polycystic ovary syndrome got good results in a Phase 2a clinical trial, according to the drug’s developer, Millendo Therapeutics Inc. of Ann Arbor.
The results were published online in the Journal of Clinical Endocrinology and Metabolism.
Polycystic ovary syndrome, the most common endocrine disease in women, and is estimated to affect 8 to 20 percent of the female population. Symptoms include irregular or absent menstruation, infertility, diabetes, and, in some cases, acne and excess hair. There are no approved therapies on the market.
Millendo’s drug candidate, called MLE4901, was well-tolerated in the clinical trial and reduced testosterone and luteinizing hormone concentrations within seven days of treatment.
Continue reading Ann Arbor Pharma Reports Good News From Clinical Trial
ANN ARBOR — Michigan’s biotech industry has added almost 2,400 jobs since 2014, according to a new research report released during the annual convention of BIO, the biotech industry organization, being held in San Francisco.
The “Value of Bioscience Innovation in Growing Jobs and Improving Quality of Life” report showed Michigan biotech employment now stands at 44,277, up 5.7 percent since the last report in 2014.
Continue reading Michigan Biotech Industry Sees Strong Job Growth
ANN ARBOR — Leaders from the Michigan biotech industry, academia, and policy realms are joining to discuss how to best drive future business growth at MichBio’s inaugural Michigan Bio-Industry Growth Summit at the Radisson Lansing on Wednesday, Feb. 3.
Continue reading Biotech Industry Sets ‘Growth Summit’
ANN ARBOR — Millendo Therapeutics Inc., the Ann Arbor pharma firm, announced an exclusive license agreement with the pharmaceutical giant AstraZeneca for the worldwide development and commercialization rights to AZD4901, a product candidate for the treatment of polycystic ovary syndrome, the most common endocrine disease in women.
Millendo also said it has secured a $62 million Series B investment led by Chevy Chase, Md.-based New Enterprise Associates Inc.
Previously known as Atterocor, Millendo is focused on developing novel approaches for the treatment of orphan and specialty endocrine diseases.
Continue reading Ann Arbor Pharma Firm Gets $62M To Commercialize Drug For Ovarian Disease
ANN ARBOR — RetroSense Therapeutics, a privately held, clinical-stage biopharmaceutical company, announced that it has secured $6 million in a Series B financing to further investigate the use of gene therapy and optogenetics to restore vision.
The investment syndicate includes existing investors, including Midland-based BlueWater Angels, and new investors RBV Capital, ExSight Capital, and Santen Pharmaceutical Co., Ltd.
Earlier in 2015, RetroSense Therapeutics closed a $7 million Series A financing, bringing total Series A and Series B investment to $13 million.
Continue reading RetroSense Raises $6M In Over-Subscribed Funding Round
ANN ARBOR — The pharmaceutical startup RetroSense Therapeutics LLC said Monday that its Investigational New Drug application for its lead drug candidate, RST-001, has received clearance from the United States Food and Drug Administration.
RetroSense is developing RST-001 for the treatment of retinitis pigmentosa, a genetic condition that leads to the progressive degeneration of rod and cone photoreceptors — the cells found in the retina that sense light — resulting in severe vision loss and blindness.
With its IND now in effect, RetroSense expects to initiate a Phase 1 and 2 clinical trial by year-end in order to evaluate the safety and, potentially, effectiveness of RST-001.
Continue reading RetroSense Gene Therapy Drug Gets FDA OK For Human Trials